SMS Pharmaceuticals Ltd has posted strong year-on-year growth in its Q1 FY26 results, with both revenue and profit showing healthy gains despite a dip in other income.
For the quarter ended June 30, 2025, revenue from operations stood at ₹196.05 crore, up 19.22% from ₹164.45 crore in the same period last year. Total income came in at ₹196.64 crore, registering an 18.59% rise YoY.
The company’s total expenses increased by 19.64% to ₹172.27 crore from ₹143.99 crore last year, largely due to higher manufacturing and employee costs.
Profit before tax for the quarter stood at ₹24.37 crore, up 11.64% from ₹21.83 crore a year ago. Net profit jumped 14.29% YoY to ₹18.71 crore from ₹16.37 crore in Q1 FY25.
Earnings per share (EPS) remained steady at ₹2.31 against ₹1.95 in the same quarter last year.
While other income dropped sharply by 56.93% YoY to ₹0.59 crore, the overall operational performance remained robust, indicating strong core business growth.
SMS Pharmaceuticals’ shares ended Friday’s trade at ₹224.50, up 4.43% from the previous close. The stock opened at ₹215.00, touched an intraday high of ₹226.60, and dipped to a low of ₹213.61. Despite the gain, the share remains well below its 52-week high of ₹398.00, but above its 52-week low of ₹176.05.
